Syntermed
Syntermed is an Atlanta-based medical imaging software company founded in 1999 that develops FDA-cleared quantitative analysis software for SPECT, PET, and CT imaging of the heart and brain, distributed globally through major OEMs (GE, Siemens, Philips, Canon) and value-added resellers to cardiology, nuclear medicine, radiology, and oncology practices.
- Company typePrivate
- Founded1999
- HeadquartersAtlanta, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Syntermed does
Syntermed, Inc. is a privately-held medical imaging software company founded in 1999 and headquartered in Atlanta, Georgia. The company develops FDA-cleared quantitative analysis software for SPECT, PET, and CT imaging of the heart and brain, serving cardiology, nuclear medicine, radiology, and oncology practices worldwide. Its core product lines include the Emory Cardiac Toolbox (now rebranded as Cardiac Toolbox/eCTB after Syntermed acquired full IP rights in September 2025) for myocardial perfusion, calcium scoring, strain analysis, blood flow, and dyssynchrony assessment; NeuroQ for FDG-PET, Amyloid, SPECT, DaTscan, and Epilepsy brain quantification against a 240-region reference database; aPROMISE, the only FDA-cleared deep-learning application for standardized PSMA PET/CT quantification in prostate cancer; and Syntermed Live, a HIPAA-compliant cloud platform for remote reading and reporting that has hosted nearly one million studies since its 2007 launch. Supporting modules include SmartReport and Syntermed IDS for natural language structured reporting and clinical decision support (230-rule engine), SyncTool, FlowTool, AdreView Tools, and amyloidosis analysis.
Syntermed generates revenue primarily through software licensing and subscriptions sold directly, through value-added resellers, and via OEM embedding arrangements with GE Medical Systems, Siemens, Philips, Canon Medical, Spectrum Dynamics, and other imaging manufacturers. The Master Service Agreement indicates recurring subscription fees with annual billing in advance and automatic renewal, supplemented by professional services (training, installation) and 24/7 support under maintenance plans. The company holds FDA 510(k) clearances, ISO 13485:2016 certification (FM 670241), CE Mark 696491, and HIPAA compliance, and Ken Van Train has guided 22 successful 510(k) submissions. Funding has historically come from operations plus over $3.3 million in NIH SBIR/STTR grants rather than external venture capital.
The company has 11-50 employees and operates globally through a combined OEM-embedded, direct enterprise sales, and event-driven GTM motion, with active participation at SNMMI and partnerships with IAEA, Lantheus (PYLARIFY AI), ASNC ImageGuide Registry, and academic institutions including Emory University and UCLA. Leadership includes Michael Lee (Chairman and CEO), Ken Van Train (President, founder-era), and Ernest V. Garcia, PhD (Chief Scientific Advisor and Endowed Professor at Emory) as the principal scientific anchor behind the cardiac algorithms.
Syntermed firmographics
Firmographics- Name
- Syntermed
- Legal name
- Syntermed, Inc.
- Website
- https://syntermed.com
- Company type
- Private
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Syntermed is an Atlanta-based medical imaging software company founded in 1999 that develops FDA-cleared quantitative analysis software for SPECT, PET, and CT imaging of the heart and brain, distributed globally through major OEMs (GE, Siemens, Philips, Canon) and value-added resellers to cardiology, nuclear medicine, radiology, and oncology practices.
- Ownership category
- akta.pro rank
Syntermed industry classification
Industry- Product category
- Nuclear Cardiology Imaging Software
- NAICS
- Computer Systems Design and Related Services (54151)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
- akta.pro secondary industries
- Nuclear Medicine & Molecular Imaging (SPECT/PET) (HLAHABAE), Non-Invasive Cardiac Imaging (Echo/CT/MRI/Nuclear) (HLAKABAE)
Keywords
Where Syntermed is headquartered
LocationHeadquarters
- HQ city
- Atlanta
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Syntermed business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Software Licensing and Subscriptions: Syntermed licenses its medical imaging software products (Emory Toolbox, NeuroQ) through OEM partnerships, direct sales, and value-added resellers. The Master Service Agreement indicates recurring subscription fees with automatic renewal terms and per-order pricing structures.
- Professional Services and Support: Training, installation, and technical support services including on-site training for additional fees and 24/7 support for customers on Software Maintenance Plans.
- OEM/Embedded Licensing: Software embedded and integrated by OEM partners including GE, Siemens, Philips, Canon Medical, and others for distribution with their imaging systems.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise/Lab Licensing |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Syntermed product offering
Product offeringCore offering
Syntermed develops, licenses, and supports FDA-cleared medical imaging software for the quantitative analysis of SPECT, PET, and CT scans of the heart and brain. Its flagship offerings include the Emory Cardiac Toolbox (Cardiac Toolbox / eCTB) for nuclear cardiology, NeuroQ for brain imaging quantification, Syntermed Live for cloud-based remote reading, and aPROMISE for PSMA PET/CT prostate cancer assessment. The company distributes its software through OEM imaging system providers, value-added resellers, and direct sales to cardiology, nuclear medicine, and radiology labs worldwide.
Product overview
Syntermed is a medical imaging software company offering a platform of specialized products for nuclear cardiology, neuroradiology, and oncology imaging analysis. The core products include Emory Cardiac Toolbox/Cardiac Toolbox (eCTB) for cardiovascular imaging quantification, NeuroQ for brain imaging analysis, and Syntermed Live for cloud-based remote reading. Additional specialized modules include SmartReport and Syntermed IDS for automated reporting and clinical decision support, SyncTool and FlowTool for cardiac dyssynchrony and blood flow analysis, AdreView Tools for sympathetic innervation imaging, Calcium Scoring and Amyloidosis Analysis for cardiac CT/PET analysis, and aPROMISE for PSMA PET/CT quantification in oncology. The company also provides advanced brain imaging tools including EQuAL for epilepsy planning, Serial Compare for longitudinal studies, DaTscan Analysis, and Amyloid Analysis within the NeuroQ platform.
Differentiator
Problem solved
Functional benefit
Brands
- Cardiac Toolbox: Advanced multi-modality solution for nuclear cardiology imaging analysis, formerly known as Emory Cardiac Toolbox. Provides tools for SPECT, PET, CT, reporting, CFR, and remote reading.
- NeuroQ
- Syntermed Live
- SmartReport
- Syntermed IDS
- aPROMISE
Products and services
- Emory Cardiac Toolbox / Cardiac Toolbox (eCTB) Advanced cardiovascular quantification software for SPECT and PET myocardial perfusion studies, providing 2D/3D displays, calcium scoring, strain analysis, dyssynchrony analysis, automatic reporting, and clinical decision support. Targets nuclear cardiology and cardiac imaging labs worldwide.
- NeuroQ Leading brain imaging analysis software providing quantification of FDG-PET, Amyloid PET, SPECT, DaTscan, and Epilepsy brain studies by comparing metabolic activity in 240 predefined brain regions to normal databases. Used by radiologists and nuclear physicians for differential diagnosis of dementia and other neurological conditions.
- Syntermed Live HIPAA-compliant cloud-based platform providing 24/7 anywhere/anytime remote reading and reporting of nuclear cardiology studies and PET brain scans without requiring VPN or LAN connections. Enables independent physician adoption with full functionality.
- aPROMISE Deep learning application for accurate, efficient, and reproducible quantification of PSMA PET/CT scans. FDA-cleared medical device providing standardized quantitative reporting of prostate cancer tumor burden. Integrates with PYLARIFY AI PSMA PET imaging from Lantheus Holdings.
- SyncTool Phase analysis software for left ventricular dyssynchrony assessment to evaluate benefits of cardiac resynchronization therapy (CRT) in heart failure patients. Used in IAEA-sponsored VISION-CRT clinical trial across 9 countries.
- FlowTool Myocardial blood flow analysis tool for computing absolute blood flow and coronary/myocardial flow reserve from dynamic PET studies. Assists in detecting balanced flow reductions in endothelial disease and triple vessel disease.
- AdreView Tools Quantitative analysis tools for I-123 AdreView SPECT studies to assess myocardial sympathetic innervation, including heart-to-mediastinum ratio calculation. Helps identify mortality risk and aid in diagnosis of congestive heart failure.
- EQuAL (Extent-specified Quantified Asymmetry-of-Lobe analysis) NeuroQ tool for non-invasive analysis of temporal lobe epilepsy to predict likelihood of seizure-free status post-surgery based on metabolic asymmetry quantification.
- Serial Compare NeuroQ feature enabling comparison of two brain studies from the same patient performed at different times, showing difference images and monitoring disease progression.
- DaTscan Analysis NeuroQ extension providing quantified comparisons for Ioflupane I-123 (DaTscan) SPECT imaging to assist in diagnosis of Parkinsonian Syndrome or Essential Tremor.
- Amyloid Analysis (NeuroQ) NeuroQ extension for quantified comparisons of Amyloid PET scans using agents including Amyvid (Lilly), NeuraCeq (Piramal), and Vizamyl (GE), with SUVr calculations and Centiloid outputs.
Quantifiable outcome
- Dementia diagnostic accuracy increases from ~70% visual read to ~90% with FDG-PET + NeuroQ quantification
- +3 more outcomes
Companies that use Syntermed
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles4 records
Syntermed technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration22 records
AI capability14 records
Feature8 records
Syntermed partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered core and major.
- GE Medical SystemscoreGE Medical Systems integrates Syntermed software including Emory Cardiac Toolbox and AdreView analysis tools with their nuclear medicine imaging systems. Long-standing OEM partnership spanning multiple product lines.
- Siemens Medical SystemscoreSiemens Medical Systems distributes Emory Cardiac Toolbox as part of their cardiac imaging solutions for SPECT and PET systems.
- Philips Medical SystemscorePhilips Medical Systems embeds Syntermed cardiac imaging analysis software with their nuclear medicine portfolio.
- Canon Medical SystemscoreCanon Medical integrates Syntermed NeuroQ brain imaging analysis software into their advanced clinical workflows for nuclear medicine.
- Spectrum DynamicsmajorSpectrum Dynamics distributes Emory Cardiac Toolbox with their nuclear cardiology imaging equipment.
- TTG Imaging SolutionsmajorTTG Imaging Solutions distributes Syntermed products including Cardiac Toolbox for nuclear cardiac imaging as part of their comprehensive solutions.
- Optum HealthcaremajorOptum Healthcare offers Syntermed Nuclear Medicine Advanced solutions through their enterprise imaging platform for change healthcare cardiology.
- CVITmajorCVIT distributes Emory Cardiac Toolbox for cardiac imaging analysis as part of their nuclear medicine product offerings.
- Mirada MedicalmajorMirada Medical distributes Syntermed diagnostic imaging software solutions for nuclear medicine applications.
- Emory UniversitycoreEmory University developed Emory Cardiac Toolbox under Ernest V. Garcia, PhD. Syntermed was exclusive licensee for 25+ years and acquired full rights in September 2025. Ongoing R&D partnership with Emory University Nuclear Cardiology laboratory.
- International Atomic Energy Agency (IAEA)majorIAEA sponsored VISION-CRT clinical trial uses SyncTool for LV Dyssynchrony analysis across heart failure patients in 9 countries including Italy, Algeria, South Africa, Pakistan, India, Colombia, Brazil, Mexico, and Vietnam.
- UCLA David Geffen School of MedicinecoreDr. Daniel Silverman, head of Neuronuclear Imaging at UCLA, collaborated on NeuroQ development and authored key reference book 'PET in the Evaluation of Alzheimer's Disease and Related Disorders'.
- Lantheus Holdings, Inc.majorSyntermed's aPROMISE integrates with PYLARIFY AI PSMA PET imaging agent from Lantheus Holdings. The only FDA-cleared standardized quantitative solution for PYLARIFY PET/CT images.
- Society of Nuclear Medicine and Molecular Imaging (SNMMI)majorSyntermed participates in SNMMI annual meetings and collaborates on education for nuclear medicine professionals.
- American Society of Nuclear Cardiology (ASNC)majorSyntermed integrates with ASNC ImageGuide Registry. Collaborative relationship for advancing nuclear cardiology standards and education.
Scale indicators8 records
Recent moves5 records
Expansion highlights6 records
Syntermed competitors and assessment
Company assessmentEmerging players
- Mediso Medical Imaging Systems: Mediso develops dedicated PET and SPECT imaging equipment and increasingly offers integrated quantification software for preclinical and clinical nuclear imaging. It competes in adjacent nuclear medicine software while also serving as a Syntermed distribution partner.
Direct peers
- Mirada Medical: Mirada Medical develops AI-enabled medical imaging software for nuclear medicine, radiation oncology, and radiology workflows. While Mirada is also a Syntermed distribution partner, its product portfolio (XD, RTx, DLCExpert) overlaps materially with Syntermed's quantification and reporting offering.
- MIM Software: MIM Software provides medical imaging analysis platforms for nuclear medicine, radiation oncology, and radiology, including quantification tools for SPECT, PET, and molecular imaging workflows. It is one of the closest direct competitors to Syntermed in nuclear medicine post-processing software.
- Hermes Medical Solutions: Hermes Medical Solutions offers molecular imaging software for SPECT, PET, and hybrid modalities with quantification, fusion, and review tools used in nuclear medicine and oncology. It directly competes with Syntermed's Emory Cardiac Toolbox and NeuroQ in nuclear medicine post-processing.
- Segami Corporation: Segami Corporation provides Oasis nuclear medicine software for SPECT, PET, and planar image processing, used widely in clinical nuclear medicine labs. It competes with Syntermed's Emory Cardiac Toolbox in cardiac and general nuclear imaging workflows.
- Thinking Systems: Thinking Systems provides nuclear medicine PACS and post-processing solutions including SPECT/PET quantification tools for clinical and research workflows. It overlaps with Syntermed's offerings in nuclear medicine imaging analysis, and is also a Syntermed distribution partner.
Broad incumbents
- Siemens Healthineers (syngo.via): Siemens syngo.via is an advanced visualization and reading platform for CT, MR, and molecular imaging, embedded across Siemens imaging installations. It competes broadly with Syntermed's cardiac and brain quantification offerings as part of a much larger OEM portfolio.
- GE Healthcare (AW Workstation / Edison): GE Healthcare's AW Workstation and Edison AI platform provide advanced visualization and AI-enabled quantification across CT, MR, PET, and SPECT. It competes with Syntermed as an incumbent alternative embedded within GE imaging systems, while also being a Syntermed OEM partner.
- Philips IntelliSpace Portal: Philips IntelliSpace Portal is a comprehensive advanced visualization and quantification platform across CT, MR, PET, and SPECT, bundled with Philips imaging hardware. It is an incumbent alternative to Syntermed's quantification products, offering overlapping capabilities as part of a much broader enterprise imaging portfolio.
- Canon Medical (Vitrea): Canon Medical's Vitrea advanced visualization platform offers multi-modality post-processing for CT, MR, and molecular imaging. It competes with Syntermed in nuclear medicine workflows while also being a Syntermed OEM distribution partner.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Syntermed social profiles
Digital presenceSyntermed compliance and trust
Trust signalCompliance7 records
Syntermed financial estimates
Financial estimateRevenue estimate
Valuation estimate
Syntermed leadership team
Management profileNumber of profiles
Profiles10 records
Syntermed funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Syntermed M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Syntermed
What does Syntermed do?
Syntermed develops, licenses, and supports FDA-cleared medical imaging software for the quantitative analysis of SPECT, PET, and CT scans of the heart and brain. Its flagship offerings include the Emory Cardiac Toolbox (Cardiac Toolbox / eCTB) for nuclear cardiology, NeuroQ for brain imaging quantification, Syntermed Live for cloud-based remote reading, and aPROMISE for PSMA PET/CT prostate cancer assessment. The company distributes its software through OEM imaging system providers, value-added resellers, and direct sales to cardiology, nuclear medicine, and radiology labs worldwide.
Is Syntermed a public or private company?
Syntermed is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Syntermed founded?
Syntermed was founded in 1999. It employs 11 to 50 people.
Where is Syntermed based?
Syntermed is headquartered in Atlanta, United States, in the North America region.
How does Syntermed make money?
Three revenue lines are on record. Software Licensing and Subscriptions are the primary driver. The others are professional Services and Support and OEM/Embedded Licensing.
Who are Syntermed's main competitors?
Mediso Medical Imaging Systems is listed as an emerging player. Direct peers are Mirada Medical, MIM Software, Hermes Medical Solutions, Segami Corporation and Thinking Systems. Broad incumbents are Siemens Healthineers (syngo.via), GE Healthcare (AW Workstation / Edison), Philips IntelliSpace Portal and Canon Medical (Vitrea).
Does Syntermed have an API?
No public API is recorded for Syntermed.
What industry is Syntermed in?
Syntermed's product category is Nuclear Cardiology Imaging Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HLAHABAE, Nuclear Medicine & Molecular Imaging (SPECT/PET). Its NAICS code is 54151 and its SIC code is 7372.